STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic...
Read More Details
Finally We wish PressBee provided you with enough information of ( US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg) )
Also on site :
- Ukraine doing West’s ‘dirty work’ in Africa – Sudanese official
- Two people killed by falling trees and thousands without power after storms sweep southern states
- Keanu Reeves Has a Most Excellent ‘Bill & Ted’ Red Carpet Reunion With Costar Alex Winter at the Tony Awards